Advanced Therapy Medicinal Products CDMO Market to Grow with a CAGR of 9.54% through 2030
Scalable manufacturing solutions and increased
investment in research and development are expected to drive the Global Advanced
Therapy Medicinal Products CDMO Market growth in the forecast period,
2026-2030.
According to TechSci Research report, “Advanced
Therapy Medicinal Products CDMO Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2030”, the Global Advanced
Therapy Medicinal Products CDMO Market was valued at USD 5.12 Billion
in 2024 and is expected to reach USD 8.87 Billion by 2030 with a CAGR of 9.54% during
the forecast period. This can be attributed to global expansion. The Global Advanced Therapy Medicinal Products CDMO Market has a global
reach, with key players operating across continents. This global presence
allows CDMOs to serve clients worldwide, tapping into diverse markets and
addressing the global demand for advanced therapies. The international
footprint of CDMOs supports the globalization of ATMP development and
distribution.
CDMOs are increasingly relying on data
analytics and artificial intelligence (AI) to improve decision-making. These
technologies assist in optimizing manufacturing processes, predicting
production issues, and ensuring product quality. Data-driven insights are
invaluable in maintaining operational efficiency.
The expansion of the market can be attributed to
several factors, including the growing demand for advanced therapies. There has
been a notable increase in investments directed towards the research and
development of pharmaceutical products in this category. Additionally, there's
a rising incidence of rare and severe disorders, encompassing conditions like
metabolic and optical diseases. The COVID-19 pandemic has significantly
impacted the advancement and production of advanced therapy medicinal products.
Among the various classes of medicines, cell-based therapy has experienced
rapid growth during the pandemic. Countries such as the USA, Jordan, China, and
Iran, among others, initiated clinical research on cell-based therapies for
treating COVID-19 patients with acute respiratory distress, coinciding with the
global spread of the disease. As of 2022, more than 80 clinical trials related
to "Mesenchymal stem cells and COVID-19" were registered on
ClinicalTrials.gov.
One of the primary catalysts for the
advanced therapy medicinal products CDMO market is the increasing number of clinical
trials focusing on ATMPs. According to a report from the American Society of
Gene and Cell Therapy, as of Q1 2022, there were 3,579 therapies in the
pipeline for gene, cell, and RNA therapies. The gene cell therapy pipeline saw
a 16% increase from Q1 2021, with CAR-T cell therapies dominating the
genetically modified cell therapy segment. Notably, 98% of CAR-T cell therapies
were in the development phase for cancer indications.
Outsourcing activities are on the rise in
this domain, as companies seek to acquire the specialized expertise necessary
for successful ATMP development and commercialization. Apart from extending
their capabilities and enhancing cash flow management, outsourcing offers
significant manufacturing advantages, including reduced investment risks.
Additionally, the relatively low incidence-to-prevalence ratios for genetic and
rare diseases make outsourcing an attractive option, as constructing an in-house
facility for producing a single gene therapy for these diseases would require a
faster cost recovery within a limited timeframe. Intensifying competition among key
companies striving to gain a substantial market share in the field is expected
to drive increased investment in research and development within the advanced
therapy medicinal products CDMO market. For instance, in January 2022,
Excellos, a cell therapy CDMO, announced the successful launch and closure of a
USD 15 million funding round from Telegraph Hill Partners. The company
specializes in providing cGMP cellular services and products, offering
manufacturing and process development expertise to clinicians and scientists
engaged in cell and gene therapy research and development.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Advanced Therapy Medicinal Products CDMO Market”
The Global Advanced Therapy Medicinal Products CDMO Market
is segmented into product, phase, indication, regional distribution, and
company.
Based on Indication, the oncology sector has firmly established itself as the fastest-growing segment in the global healthcare market, driven by the increasing global burden of cancer. With the rise in cancer prevalence, attributed to factors like aging populations, changing lifestyles, and environmental influences, there is an accelerating demand for innovative cancer treatments. These dynamics make oncology not only a dominant force but also a rapidly expanding area in healthcare.
Several factors contribute to the sector's growth. The increasing effectiveness of early detection methods, combined with advancements in therapeutic development, has created a strong demand for more sophisticated and personalized treatment options. As cancer diagnoses become more frequent, the need for targeted therapies, such as immunotherapies and personalized medicine, continues to surge. Breakthrough treatments like CAR-T cell therapies, immune checkpoint inhibitors, and gene therapies have significantly improved patient outcomes, further propelling the market's expansion. In addition, substantial investments from pharmaceutical and biotech companies in oncology R&D have led to remarkable progress in precision oncology, tailoring treatments to both the genetic profile of tumors and the individual patient. Collaborative efforts between academia, research institutions, and pharmaceutical companies are accelerating innovation and enabling the rapid development of more effective, targeted, and less toxic therapies. The oncology sector's rapid expansion is also supported by global initiatives to improve access to cutting-edge treatments, thereby fostering more comprehensive care. As research continues to yield promising results, oncology is expected to maintain its position as the fastest-growing and dominant sector in healthcare.
Based on region, Asia-Pacific region was emerging as the
second-dominant force in the global Advanced Therapy Medicinal Product CDMO market, following
Europe. This shift can be attributed to several key factors, including rapid
economic growth, increased healthcare investments, expanding biopharmaceutical
industries, and a growing demand for innovative therapies. Asia-Pacific
countries, particularly Japan, China, South Korea, and India, are witnessing
significant advancements in both research and infrastructure, positioning the
region as a critical player in the ATMP sector.
One of the primary drivers behind the
growth of the Global Advanced Therapy Medicinal Products CDMO Market in Asia-Pacific is the increasing investment in
healthcare infrastructure and biotechnology. Governments and private
organizations are allocating substantial resources to foster research and
development in gene therapy, cell therapy, and tissue engineering. This support
is not only encouraging innovation but also creating an attractive environment
for international collaborations. Furthermore, the Asia-Pacific region benefits
from a lower cost of production, enabling cost-effective manufacturing
solutions for ATMPs without compromising on quality. This makes the region a
desirable location for outsourcing and production by global pharmaceutical
companies. The Asia-Pacific region
boasts a highly skilled and growing workforce, particularly in countries like
Japan and South Korea, where advanced technologies and expertise in cellular
biology, genetic engineering, and biotechnology are rapidly advancing.
Countries like China and India have also been increasing their focus on the
biotechnology and pharmaceutical sectors, with an increasing number of contract
manufacturers offering specialized services in cell-based and gene therapies.
The presence of a skilled labor force and competitive pricing further
strengthens the region’s appeal as a destination for ATMP manufacturing and
development.
Major companies operating in Global Advanced
Therapy Medicinal Products CDMO Market are:
- Celonic
AG
- Rentschler
Biopharma SE
- Catalent,
Inc.
- Lonza
Group AG
- WuXi
Advanced Therapies
- Minaris
Regenerative Medicine, LLC
- Pluri
Biotech Ltd.
- REPROCELL
USA Inc.
- BioPhorum
Operations Group
- Cellares
Corporation
Download Free Sample Report
Customers can also request for 10%
free customization on this report
“The
future of the Global Advanced Therapy Medicinal Products CDMO Market is
poised for substantial growth, driven by increasing demand for gene therapies,
cell therapies, and tissue-engineered products. As regulatory frameworks evolve
and manufacturing technologies advance, the market will see greater emphasis on
efficiency, scalability, and cost-effective production. Strategic partnerships
between pharmaceutical companies and CDMOs will accelerate innovation and
streamline production processes. Furthermore, the Asia-Pacific region, with its
growing healthcare infrastructure and cost advantages, is expected to become a
key player in this space. Additionally, advancements in personalized medicine
and the rising focus on rare and chronic diseases will further fuel the demand
for ATMPs, creating new opportunities and expanding the market globally.,” said Mr. Karan Chechi,
Research Director of TechSci Research, a research-based management consulting
firm.
“Advanced Therapy
Medicinal Products CDMO Market - Global Industry Size, Share, Trends,
Opportunity, and Forecast, Segmented By Product (Gene
Therapy, Cell Therapy, Tissue Engineered, Others), By Phase (Phase I, Phase II,
Phase III, Phase IV), By Indication (Oncology, Cardiology, Central Nervous
System, Musculoskeletal, Infectious disease, Immunology & inflammation,
Others), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global
Advanced Therapy Medicinal Products CDMO Market and provides statistics &
information on market size, structure and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Advanced Therapy Medicinal Products CDMO Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com